FRANK CHEN: Open Payments
NPI 1932294584 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$359,008 in 382 payments from 12 companies in 2025. Trend: 2023 $173,928 · 2024 $149,065 · 2025 $359,008
Speaker / faculty: $292,953Travel & lodging: $25,145Honoraria: $16,000Consulting: $15,746Food & beverage: $9,164
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 87 | $112,822 |
| E.R. Squibb & Sons, L.L.C. | 111 | $106,376 |
| Alkermes, Inc. | 118 | $85,685 |
| Otsuka America Pharmaceutical, Inc. | 29 | $27,915 |
| Luye Pharma (USA) Ltd. | 20 | $18,463 |
| Eli Lilly and Company | 2 | $7,300 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $222 |
| ABBVIE INC. | 3 | $66 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
Products named: UZEDY, COBENFY, LYBALVI, ABILIFY MAINTENA, ERZOFRI EXTENDED-RELEASE, ARISTADA, REJOYN, VRAYLAR.
Industry payments across TX — which companies pay providers there.
